Hyloris Pharmaceuticals SA
XBRU:HYL
Hyloris Pharmaceuticals SA
XBRU:HYL
Price:
11.7 EUR
Updated:
Jun 10, 2024
Section:
Relative Value
The Relative Value of one
HYL
stock under the Base Case scenario is
5.66
EUR.
Compared to the current market price of 11.7 EUR,
Hyloris Pharmaceuticals SA
is
Overvalued by 52%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
HYL
Relative Value
Base Case
5.66
EUR
Overvaluation 52%
Valuation Multiples
Multiples Across Competitors
HYL Competitors Multiples
Hyloris Pharmaceuticals SA Competitors
Hyloris Pharmaceuticals SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| BE |
|
Hyloris Pharmaceuticals SA
XBRU:HYL
|
327.6m EUR | 116.4 | -20.8 | -19 | -18.5 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
807.8B USD | 22.5 | 131.6 | 64.3 | 73.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.4T DKK | 17.9 | 49.1 | 36.6 | 40.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
354B USD | 4.1 | 9.2 | 11.3 | 14.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
330.9B USD | 5.4 | 143.5 | 35.7 | 58.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
195.3B GBP | 5.2 | 39.2 | 175.3 | 279.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
191.7B CHF | 3.3 | 16.7 | 9.4 | 11.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
184.7B CHF | 3.5 | 11.7 | 8.9 | 13.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
162B USD | 2.9 | -524.2 | 12.7 | 20.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
